Journal ArticleDOI
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
A. Rizzo,A. Cusmai,Silvana Acquafredda,Francesco Giovannelli,Luciana Rinaldi,A. Misino,G. Palmiotti +6 more
TLDR
An overview of recent clinical studies of neoadjuvant immune checkpoint inhibitors in patients with triple-negative breast cancer, especially focusing on the recently presented and published KEYNOTE-522, IMpassion031 and GeparNUEVO trials is provided.Abstract:
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new diagnoses of early breast cancer. Novel systemic treatment options have recently been assessed as part of the neoadjuvant approach, such as the addition of immune checkpoint inhibitors to cytotoxic chemotherapy. However, several questions remain unanswered, including the identification of predictors of response to immunotherapy in this setting, and further efforts aimed at identifying reliable predictors and clarifying the effective role of PD-L1 status, tumor mutational burden, tumor-infiltrating lymphocytes and other biomarkers are warranted. Herein we will provide an overview of recent clinical studies of neoadjuvant immune checkpoint inhibitors in patients with triple-negative breast cancer, especially focusing on the recently presented and published KEYNOTE-522, IMpassion031 and GeparNUEVO trials.read more
Citations
More filters
Journal ArticleDOI
Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies
TL;DR: In this article , the authors showed that the addition of dendritic cell vaccines (DCV) to NAC could induce immune responses in those patients with residual disease (RD) by transforming the tumor microenvironment.
Journal ArticleDOI
Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells
M Sánchez-León,Carlos Jiménez-Cortegana,Silvia Silva Romeiro,Carmen Garnacho,L. De La Cruz Merino,Daniel J. García-Domínguez,Lourdes Hontecillas-Prieto,Víctor Sánchez-Margalet +7 more
TL;DR: In this paper , the role of myeloid-derived suppressor cells (MDSC) as a therapeutic target in breast cancer was described, which has been associated with worse clinical stage, metastatic burden, and poor efficacy of immunotherapies.
Journal ArticleDOI
Improved Survival of Young Patients With Breast Cancer 40 Years and Younger at Diagnosis
TL;DR: In this article , the authors reported the outcome of patients with breast cancer 40 years and younger, and retrieved demographic, clinicopathologic, treatment-related, disease progression, and survival data from electronic medical records.
Journal ArticleDOI
Germline BRCA 1 Positive Breast Ovarian Cancer Syndrome
Aref Chehal,Ashraf Alakkad +1 more
TL;DR: A 57-year-old female patient who presented with a mass in her right breast in June 2022 was evaluated further by as discussed by the authors , where mammography showed an ill-defined micro lobulated lesion 4 cm from the nipple, measuring 43 x 27 mm with a few microcalcifications.
Journal ArticleDOI
Improved Survival of Young Patients With Breast Cancer 40 Years and Younger at Diagnosis.
Nagi S. El Saghir,Lana E. Khalil,Joud El Dick,Rula W. Atwani,N. Safi,Maya Charafeddine,M Chaccour,Arafat Tfayli,Hazem I. Assi,Jaber Abbas,Zeina Ayoub,Eman Sbaity,Hiba A. Moukadem +12 more
TL;DR: In this article , the authors report the outcome of patients with breast cancer 40 years and younger, and report survival rates of 89% at 5 years and 76% at 10 years with modern multidisciplinary management.
References
More filters
Journal ArticleDOI
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Journal ArticleDOI
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M. Samstein,Chung-Han Lee,Chung-Han Lee,Alexander N. Shoushtari,Alexander N. Shoushtari,Matthew D. Hellmann,Matthew D. Hellmann,Ronglai Shen,Yelena Y. Janjigian,Yelena Y. Janjigian,David Barron,Ahmet Zehir,Emmet Jordan,Antonio Omuro,Thomas Kaley,Sviatoslav M. Kendall,Robert J. Motzer,Robert J. Motzer,A. Ari Hakimi,Martin H. Voss,Martin H. Voss,Paul Russo,Jonathan E. Rosenberg,Jonathan E. Rosenberg,Gopa Iyer,Gopa Iyer,Bernard H. Bochner,Dean F. Bajorin,Dean F. Bajorin,Hikmat Al-Ahmadie,Jamie E. Chaft,Jamie E. Chaft,Charles M. Rudin,Charles M. Rudin,Gregory J. Riely,Gregory J. Riely,Shrujal S. Baxi,Shrujal S. Baxi,Alan L. Ho,Alan L. Ho,Richard J. Wong,David G. Pfister,David G. Pfister,Jedd D. Wolchok,Jedd D. Wolchok,Christopher A. Barker,Philip H. Gutin,Cameron Brennan,Viviane Tabar,Ingo K. Mellinghoff,Lisa M. DeAngelis,Charlotte E. Ariyan,Nancy Y. Lee,William D. Tap,William D. Tap,Mrinal M. Gounder,Mrinal M. Gounder,Sandra P. D'Angelo,Sandra P. D'Angelo,Leonard B. Saltz,Leonard B. Saltz,Zsofia K. Stadler,Zsofia K. Stadler,Howard I. Scher,Howard I. Scher,José Baselga,José Baselga,Pedram Razavi,Pedram Razavi,Christopher A. Klebanoff,Christopher A. Klebanoff,Rona Yaeger,Rona Yaeger,Neil H. Segal,Neil H. Segal,Geoffrey Y. Ku,Geoffrey Y. Ku,Ronald P. DeMatteo,Marc Ladanyi,Naiyer A. Rizvi,Michael F. Berger,Nadeem Riaz,David B. Solit,Timothy A. Chan,Luc G. T. Morris +84 more
TL;DR: Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
Journal ArticleDOI
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Timothy A. Chan,Mark Yarchoan,Elizabeth M. Jaffee,Charles Swanton,Sergio A. Quezada,Albrecht Stenzinger,Solange Peters +6 more
TL;DR: TMB, in concert with PD-L1 expression, has been demonstrated to be a useful biomarker for ICB selection across some cancer types; however, further prospective validation studies are required.
Journal ArticleDOI
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study
Barbara Burtness,Kevin J. Harrington,Richard Greil,Denis Soulières,Makoto Tahara,Gilberto de Castro,Amanda Psyrri,Neus Baste,Prakash Neupane,Åse Bratland,Thorsten Fuereder,Brett G.M. Hughes,Ricard Mesia,Nuttapong Ngamphaiboon,Tamara Rordorf,Wan Zamaniah Wan Ishak,Ruey-Long Hong,René González Mendoza,Ananya Roy,Yayan Zhang,Burak Gumuscu,Jonathan D. Cheng,Fan Jin,Danny Rischin,Danny Rischin,Guillermo Lerzo,Marcelo Tatangelo,Mirta Varela,J. J. Zarba,Michael Boyer,Hui K Gan,Bo Gao,Brett Hughes,Girish Mallesara,Anne W. Taylor,Martin Burian,Carlos H. Barrios,Dalvaro Oliveira de Castro Junior,Gilberto de Castro,Fabio Franke,Gustavo Girotto,Iane Pinto Figueiredo Lima,Ulisses Ribaldo Nicolau,Gustavo Dix Junqueira Pinto,Lucas Vieira dos Santos,Ana Paula Victorino,Neil Chua,Felix Couture,Richard Gregg,Aaron R. Hansen,John Hilton,Joy McCarthy,Rodrigo Ascui,Pablo Gonzalez,Luis Villanueva,Marco Torregroza,Angela Zambrano,Petra Holeckova,Zdenek Kral,Bohuslav Melichar,Jana Prausova,Milan Vosmik,Maria Andersen,Niels Gyldenkerne,Hannes Jurgens,Kadri Putnik,Petri Reinikainen,Viktor Gruenwald,Simon Laban,Gerasimos Aravantinos,Ioannis Boukovinas,Vassilis Georgoulias,Dora Kwong,Yousuf Al-Farhat,Tibor Csoszi,Jozsef Erfan,Geza Horvai,Laszlo Landherr,Éva Remenár,Agnes Ruzsa,Judit Szota,Salem Billan,Iris Gluck,Orit Gutfeld,Aron Popovtzer,Marco Benasso,Simona Bui,Vittorio Ferrari,Lisa Licitra,Franco Nolè,Takashi Fujii,Yasushi Fujimoto,Nobuhiro Hanai,Hiroki Hara,Koji Matsumoto,Kenji Mitsugi,Nobuya Monden,Masahiro Nakayama,Kenji Okami,Nobuhiko Oridate,Kiyoto Shiga,Yasushi Shimizu,Masashi Sugasawa,Masanobu Takahashi,Shunji Takahashi,Kaoru Tanaka,Tsutomu Ueda,Hironori Yamaguchi,Tomoko Yamazaki,Ryuji Yasumatsu,Tomoya Yokota,Tomokazu Yoshizaki,Iveta Kudaba,Zinaida Stara,Soon Keat Cheah,Jose Aguilar Ponce,Carlos Hernandez Hernandez,Francisco Medina Soto,Jan Buter,Ann Hoeben,Sjoukje F. Oosting,Karijn P M Suijkerbuijk,Aase Bratland,Marianne Brydoey,Renzo Alvarez,Luis Mas,Priscilla Caguioa,John Querol,Eugenio Emmanuel Regala,Maria Belen Tamayo,Ellie May Villegas,Andrzej Kawecki,Andrey Karpenko,Arkadiy Klochikhin,Alexey Smolin,Oleg Zarubenkov,Boon Cher Goh,Graham Cohen,Johanna du Toit,Christa Jordaan,Gregory Landers,Paul Ruff,Waldemar Szpak,Neonyana Tabane,Irene Brana,Lara Carmen Iglesias Docampo,Javier Lavernia,Edvard Abel,Valentina Muratidu,Niels Nielsen,Valerie Cristina,Sacha Rothschild,Hung Ming Wang,Muh Hwa Yang,Su Peng Yeh,Chia Jui Yen,Nopadol Soparattanapaisarn,Virote Sriuranpong,Sercan Aksoy,Irfan Cicin,Meltem Ekenel,Hakan Harputluoglu,Ozgur Ozyilkan,Kevin J. Harrington,Sanjiv S. Agarwala,Haythem Ali,Robert Alter,Daniel Anderson,Justine Bruce,Nicholas Campbell,Miguel Conde,John F. Deeken,William Edenfield,Lawrence E. Feldman,Elizabeth Gaughan,Basem Goueli,Balazs Halmos,Upendra P. Hegde,Brian Hunis,Robert Jotte,Anand B. Karnad,Saad A. Khan,Noel Laudi,Douglas Laux,Danko Martincic,Steven McCune,Dean McGaughey,Krzysztof Misiukiewicz,Deborah Mulford,Eric Nadler,Johannes Nunnink,James Ohr,Meaghan O'Malley,Brian Patson,Doru Paul,Elizabeta Popa,Steven Francis Powell,Rebecca Redman,Vincent Rella,Chaio Rocha Lima,Abirami Sivapiragasam,Yungpo Su,Ammar Sukari,Stuart Wong,Emrullah Yilmaz,Jeffrey Yorio +205 more
TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.
Journal ArticleDOI
Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid,Javier Cortes,Lajos Pusztai,Heather L. McArthur,Sherko Kümmel,Jonas Bergh,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Theodoros Foukakis,Peter A. Fasching,Fatima Cardoso,Michael Untch,L. Jia,Vassiliki Karantza,Jing Zhao,Gursel Aktan,Rebecca Dent,Joyce O'Shaughnessy,Keynote Investigators +21 more
TL;DR: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among thosewho received placebo plusNeoadjuant chemotherapy.